Factors affecting delivery of antiviral drugs to the brain

Reviews in Medical Virology

Volumn 15, Issue 2, 2005, Pages 105-133

  Strazielle, Nathalie ^a   Ghersi Egea, Jean François ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ACYCLIC NUCLEOSIDE; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMANTADINE DERIVATIVE; AMPRENAVIR PHOSPHATE; ANTIVIRUS AGENT; ATAZANAVIR; ATEVIRDINE; EFAVIRENZ; ENFUVIRTIDE; FOSCARNET; GANCICLOVIR; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; OSELTAMIVIR; PEPTIDE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PROBENECID; PROTEINASE INHIBITOR; RIBAVIRIN; RIMANTADINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIALIC ACID DERIVATIVE; TENOFOVIR DISOPROXIL; TOPOTECAN; UNINDEXED DRUG; VALACICLOVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN PROTECTION; CAPILLARY ENDOTHELIUM; CELL INTERACTION; CELL METABOLISM; CELL SURFACE; CELL TRANSPORT; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROVASCULAR ACCIDENT; CHOROID PLEXUS; CHOROID VASCULARIZATION; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG TRANSPORT; ENCEPHALITIS; ENDOTHELIUM CELL; EPITHELIUM CELL; ERYTHROCYTE; HUMAN; IMPEDANCE; INFLUENZA; INFLUENZA VIRUS; JC VIRUS; LIPID SOLUBILITY; MEASLES VIRUS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SIDE EFFECT; SUBACUTE SCLEROSING PANENCEPHALITIS; TIGHT JUNCTION; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; BRAIN; BRAIN DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; VIRUS DISEASES;

EID: 14844297314     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.454     Document Type: Review

References (186)

1. Kennedy PG. Viral encephalitis: causes, differential diagnosis, and management. J Neurol Neurosurg Psychiatry 2004; 75(Suppl. 1): 10-15.
2. Ljungman P. Viral infections: current diagnosis and treatment. Hematol J 2004; 5(Suppl. 3): S63-S68.
3. Caserta MT, Hall CB, Schnabel K, et al. Neuroinvasion and persistence of human herpesvirus 6 in children. J Infect Dis 1994; 170: 1586-1589.
4. Petito CK. Human immunodeficiency virus type 1 compartmentalization in the central nervous system. J Neurovirol 2004; 10(Suppl. 1): 21-24.
5. Gray F, Chretien F, Vallat-Decouvelaere AV, et al. The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol 2003; 62: 429-440.
6. Brew BJ, Pemberton L, Cunningham P, et al. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 1997; 175: 963-966.
7. Cinque P, Vago L, Marenzi R, et al. Herpes simplex virus infections of the central nervous system in human immunodeficiency virus-infected patients: clinical management by polymerase chain reaction assay of cerebrospinal fluid. Clin Infect Dis 1998; 27: 303-309.
8. Maschke M, Kastrup O, Diener HC. CNS manifestations of cytomegalovirus infections: diagnosis and treatment. CNS Drugs 2002; 16: 303-315.
9. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004; 30: 115-133.
10. Portegies P, Solod L, Cinque P, et al. Guidelines for the diagnosis and management of neurological complications of HIV infection. Eur J Neurol 2004; 11: 297-304.
11. Davson H, Segal MB. Physiology of the CSF and the Blood-brain Barriers. CRC Press: Boca Raton, New York, London, Tokyo, 1996.
12. Knopf PM, Cserr HF, Nolan SC, et al. Physiology and immunology of lymphatic drainage of interstitial and cerebrospinal fluid from the brain. Neuropathol Appl Neurobiol 1995; 21: 175-180.
13. Harling-Berg CJ, Park TJ, Knopf PM. Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation. J Neuroimmunol 1999; 101: 111-127.
14. Ghersi-Egea JF, Finnegan W, Chen JL, et al. Rapid distribution of intraventricularly administered sucrose into cerebrospinal fluid cisterns via subarachnoid velae in rat. Neuroscience 1996; 75: 1271-1288.
15. Segal MB. The choroid plexuses and the barriers between the blood and the cerebrospinal fluid. Cell Mol Neurobiol 2000; 20: 183-196.
16. Blaney SM, Daniel MJ, Harker AJ, et al. Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates. Antimicrob Agents Chemother 1995; 39: 2779-2782.
17. Baker SD, Heideman RL, Crom WR, et al. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 1996; 37: 195-202.
18. Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J Physiol 1990; 429: 47-62.
19. Wolburg H, Wolburg-Buchholz K, Kraus J, et al. Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol (Berl) 2003; 105: 586-592.
20. Furuse M, Furuse K, Sasaki H, et al. Conversion of zonulae occludentes from tight to leaky strand type by introducing claudin-2 into Madin-Darby canine kidney I cells. J Cell Biol 2001; 153: 263-272.
21. Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-2524.
22. Gao B, Stieger B, Noe B, et al. Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 1999; 47: 1255-1264.
23. Mori S, Takanaga H, Ohtsuki S, et al. Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab 2003; 23: 432-440.
24. Lippoldt A, Liebner S, Andbjer B, et al. Organization of choroid plexus epithelial and endothelial cell tight junctions and regulation of claudin-1, -2 and -5 expression by protein kinase C. Neuroreport 2000; 11: 1427-1431.
25. Speake T, Whitwell C, Kajita H, et al. Mechanisms of CSF secretion by the choroid plexus. Microsc Res Tech 2001; 52: 49-59.
26. Keep RF, Jones HC. A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat. Brain Res Dev Brain Res 1990; 56: 47-53.
27. Strazielle N, Ghersi-Egea JF. Demonstration of a coupled metabolism-efflux process at the choroid plexus as a mechanism of brain protection toward xenobiotics. J Neurosci 1999; 19: 6275-6289.
28. Strazielle N, Khuth ST, Ghersi-Egea JF. Detoxification systems, passive and specific transport for drugs at th blood-CSF barrier in normal and pathological situations. Adv Drug Deliv Rev 2004; 56: 1717-1740.
29. Elsinga PH, Hendrikse NH, Bart J, et al. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des 2004; 10: 1493-1503.
30. Unadkat JD. Using PET to image transport activity at the blood-brain and the placental barrier in human and non-human primate. In Proceedings of the EUFEPS Conference on Drug Transporters, Approaches in ADME Research, Copenhagen, Denmark; April 19-21, 2004; 9-10.
31. Rolinski B, Bogner JR, Sadri I, et al. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 192-197.
32. Foudraine NA, Hoetelmans RM, Lange JM, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998; 351: 1547-1551.
33. Haas DW, Clough LA, Johnson BW, et al. Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res Hum Retroviruses 2000; 16: 1491-1502.
34. Haas DW, Johnson B, Nicotera J, et al. Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob Agents Chemother 2003; 47: 2131-2137.
35. Fenstermacher JD. The pharmacology of the blood-brain barrier. In Implications of the Blood-Brain Barrier and its Manipulation, Neuwelt E (ed.). Plenum: New York, 1989; 137-155.
36. Chen JL, Wei L, Bereczki D, et al. Virtually unaltered permeability-surface area products imply little capillary recruitment in brain with hypoxia. Microcirculation 1994; 1: 35-47.
37. Golden PL, Pollack GM. Blood-brain barrier efflux transport. J Pharm Sci 2003; 92: 1739-1753.
38. Smith QR. A review of blood-brain barrier transport techniques. Methods Mol Med 2003; 89: 193-208.
39. Bereczki D, Wei L, Acuff V, et al. Technique-dependent variations in cerebral microvessel blood volumes and hematocrits in the rat. J Appl Physiol 1992; 73: 918-924.
40. Shen DD, Artru AA, Adkison KK. Principle and applicability of CSF sampling for the assessement of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 2004; 56: 1825-1857.
41. Strazielle N, Preston JE. Transport across the choroid plexuses in vivo and in vitro. Methods Mol Med 2003; 89: 291-304.
42. Redzic ZB, Segal MB, Markovic ID, et al. The characteristics of basolateral nucleoside transport in the perfused sheep choroid plexus and the effect of nitric oxide inhibition on these processes. Brain Res 1997; 767: 26-33.
43. Regina A, Koman A, Piciotti M, et al. Mrp1 multidrug resistance- associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 1998; 71: 705-715.
44. Strazielle N, Belin MF, Ghersi-Egea JF. Choroid plexus controls brain availability of anti-HIV nucleoside analogs via pharmacologically inhibitable organic anion transporters. Aids 2003; 17: 1473-1485.
45. Shu C, Shen H, Teuscher NS, et al. Role of PEPT2 in peptide/mimetic trafficking at the blood-cerebrospinal fluid barrier: studies in rat choroid plexus epithelial cells in primary culture. J Pharmacol Exp Ther 2002; 301: 820-829.
46. Terasaki T, Hosoya K. Conditionally immortalized cell lines as a new in vitro model for the study of barrier functions. Biol Pharm Bull 2001; 24: 111-118.
47. Yalaz K, Anlar B, Oktem F, et al. Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology 1992; 42: 488-491.
48. Tomoda A, Nomura K, Shiraishi S, et al. Trial of intraventricular ribavirin therapy for subacute sclerosing panencephalitis in Japan. Brain Dev 2003; 25: 514-517.
49. Levy RM, Major E, Ali MJ, et al. Convection-enhanced intraparenchymal delivery (CEID) of cytosine arabinoside (AraC) for the treatment of HIV-related progressive multifocal leukoencephalopathy (PML). J Neurovirol 2001; 7: 382-385.
50. Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998; 338: 1345-1351.
51. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004; 56: 3-17.
52. Seki T, Sato N, Hasegawa T, et al. Nasal absorption of zidovudine and its transport to cerebrospinal fluid in rats. Biol Pharm Bull 1994; 17: 1135-1137.
53. Yajima T, Juni K, Saneyoshi M, et al. Direct transport of 2′,3′-didehydro-3′-deoxythymidine (D4T) and its ester derivatives to the cerebrospinal fluid via the nasal mucous membrane in rats. Biol Pharm Bull 1998; 21: 272-277.
54. Gibbs JE, Thomas SA. The distribution of the anti-HIV drug, 2′3′-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J Neurochem 2002; 80: 392-404.
55. Fenstermacher JD, Bereczki D, Wei L, et al. The pharmacology of the blood-brain barrier and cerebral extracellular fluid. In CNS Barriers and Modern CSF Diagnostics, Felgenhauer K, Holzgraefe M, Prange HW (eds). VCH Verlags: Weinheim, New York, 1993; 31-40.
56. Pardridge WM, Sakiyama R, Fierer G. Transport of propranolol and lidocaine through the rat blood-brain barrier: primary role of globulin-bound drug. J Clin Invest 1983; 71: 900-908.
57. Cornford EM, Diep CP, Pardridge WM. Blood-brain barrier transport of valproic acid. J Neurochem 1985; 44: 1541-1550.
58. Wu D, Clement JG, Pardridge WM. Low blood-brain barrier permeability to azidothymidine (AZT), 3TC, and thymidine in the rat. Brain Res 1998; 791: 313-316.
59. Thomas SA, Bye A, Segal MB. Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid. J Pharmacol Exp Ther 2001; 298: 947-953.
60. Lin JH, Chiba M, Balani SK, et al. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996; 24: 1111-1120.
61. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-294.
62. Flexner CW. Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring. Top HIV Med 2003; 11: 40-44.
63. Hengge UR, Brockmeyer NH, Malessa R, et al. Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis. Antimicrob Agents Chemother 1993; 37: 1010-1014.
64. Lopez-Cortes LF, Ruiz-Valderas R, Lucero-Munoz MJ, et al. Intravitreal, retinal, and central nervous system foscarnet concentrations after rapid intravenous administration to rabbits. Antimicrob Agents Chemother 2000; 44: 756-759.
65. Chang M, Sood VK, Wilson GJ, et al. Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdine in mice. Drug Metab Dispos 1997; 25: 828-839.
66. Tashima KT, Caliendo AM, Ahmad M, et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HTV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis 1999; 180: 862-864.
67. Chang M, Sood VK, Wilson GJ, et al. Absorption, distribution, metabolism, and excretion of atevirdine in the rat. Drug Metab Dispos 1998; 26: 1008-1018.
68. Glynn SL, Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antirerroviral agents. J Pharm Sci 1998; 87: 306-310.
69. Blaney SM, Cole DE, Balls FM, et al. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 1993; 53: 725-727.
70. Zamboni WC, Luftner DI, Egorin MJ, et al. The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid. Ann Oncol 2001; 12: 119-122.
71. El-Gizawy SA, Hedaya MA. Comparative brain tissue distribution of camptothecin and topotecan in the rat. Cancer Chemother Pharmacol 1999; 43: 364-370.
72. Straathof CS, van den Bent MJ, Loos WJ, et al. The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration. J Neurooncol 1999; 42: 117-122.
73. Geskey JM, Thomas NJ. Amantadine penetration into cerebrospinal fluid of a child with influenza A encephalitis. Pediatr Infect Dis J 2004; 23: 270-272.
74. Spector R. Transport of amantadine and rimantadine through the blood-brain barrier. J Pharmacol Exp Ther 1988; 244: 516-519.
75. Kornhuber J, Quack G, Danysz W, et al. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995; 34: 713-721.
76. Hesselink MB, De Boer BG, Breimer DD, et al. Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study. Pharm Res 1999; 16: 637-642.
77. Strazielle N, Ghersi-Egea JF. Implication of blood-brain interfaces in cerebral drug metabolism and drug metabolite disposition. In Molecular Drug Metabolism and Toxicology, Williams GM, Aruoma OI (eds). OICA International: London UK, 2000; 181-200.
78. Johnson MD, Anderson BD. Localization of purine metabolizing enzymes in bovine brain microvessel endothelial cells: an enzymatic blood-brain barrier for dideoxynucleosides? Pharm Res 1996; 13: 1881-1886.
79. Good SS, Koble CS, Crouch R, et al. Isolation and characterization of an ether glucuronide of zidovudine, a major metabolite in monkeys and humans. Drug Metab Dispos 1990; 18: 321-326.
80. McDowell JA, Chittick GE, Ravitch JR, et al. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 1999; 43: 2855-2861.
81. Herber R, Magdalou J, Haumont M, et al. Glucuronidation of 3′-azido-3′-deoxythymidine in human liver microsomes: enzyme inhibition by drugs and steroid hormones. Biochim Biophys Acta 1992; 1139: 20-24.
82. Singhal D, Morgan ME, Anderson BD. Role of brain tissue localized purine metabolizing enzymes in the central nervous system delivery of anti-HIV agents 2′-beta-fluoro-2′,3′-dideoxyinosine and 2′-beta-fluoro- 2′,3′-dideoxyadenosine in rats. Pharm Res 1997; 14: 786-792.
83. Beach JW. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin Ther 1998; 20: 2-25.
84. Kusuhara H, Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug Discov Today 2001; 6: 150-156.
85. Kusuhara H, Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2). Drug Discov Today 2001; 6: 206-212.
86. Graff CL, Pollack GM. Drug transport at the blood-brain barrier and the choroid plexus. Curr Drug Metab 2004; 5: 95-108.
87. Smith DE, Johanson CE, Keep RF. Peptide and peptide analog transport systems at the blood-CSF barrier. Adv Drug Deliv Rev 2004; 56: 1765-1791.
88. Kusuhara H, Sugiyama Y. Efflux transport systems for organic anions and cations at the blood-CSF barrier. Adv Drug Deliv Rev 2004; 56: 1741-1763.
89. Lin JH. How significant is the role of P-glycoprotein in drug absorption and brain uptake? Drugs Today 2004; 40: 5-22.
90. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003; 55: 3-29.
91. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37: 3594-3601.
92. Polli JW, Jarrett JL, Studenberg SD, et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 1999; 16: 1206-1212.
93. Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000; 28: 655-660.
94. Huisman MT, Smit JW, Wiltshire HR, et al. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 2001; 59: 806-813.
95. Edwards JE, Brouwer KR, McNamara PJ. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats. Antimicrob Agents Chemother 2002; 46: 2284-2286.
96. Anthonypillai C, Sanderson RN, Gibbs JE, et al. The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig. J Pharmacol Exp Ther 2004; 308: 912-920.
97. Kravcik S, Gallicano K, Roth V, et al. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J Acquir Immune Defic Syndr 1999; 21: 371-375.
98. Sadler BM, Chittick GE, Polk RE, et al. Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects. J Clin Pharmacol 2001; 41: 386-396.
99. Solas C, Lafeuillade A, Halfon P, et al. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 238-243.
100. Aweeka F, Jayewardene A, Staprans S, et al. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1 - infected patients with and without AIDS dementia complex. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 39-43.
101. Rao W, Dahlheimer JL, Bardgett ME, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 1999; 96: 3900-3905.
102. Lee YJ, Kusuhara H, Sugiyama Y. Do multidrug resistance-associated protein-1 and -2 play any role in the elimination of estradiol-17 beta-glucuronide and 2,4-dinitrophenyl-S-glutathione across the blood-cerebrospinal fluid barrier? J Pharm Sci 2004; 93: 99-107.
103. Choudhuri S, Cherrington NJ, Li N, et al. Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. Drug Metab Dispos 2003; 31: 1337-1345.
104. Leggas M, Adachi M, Scheffer GL, et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 2004; 24: 7612-7621.
105. Berezowski V, Landry C, Dehouck MP, et al. Contribution of glial cells and pericytes to the mRNA profiles of P-glycoprotein and multidrug resistance-associated proteins in an in vitro model of the blood-brain barrier. Brain Res 2004; 1018: 1-9.
106. Zhang Y, Han H, Elmquist WF, et al. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res 2000; 876: 148-153.
107. Miller DS, Nobmann SN, Gutmann H, et al. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol 2000; 58: 1357-1367.
108. Sugiyama D, Kusuhara H, Lee YJ, et al. Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-D-17beta-glucuronide (E217betaG) across the blood-brain barrier. Pharm Res 2003; 20: 1394-1400.
109. Cisternino S, Mercier C, Bourasset F, et al. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 2004; 64: 3296-3301.
110. Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001; 42: 1501-1506.
111. Huisman MT, Smit JW, Crommentuyn KM, et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. Aids 2002; 16: 2295-2301.
112. Potschka H, Fedrowitz M, Loscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 2003; 306: 124-131.
113. Schuetz JD, Connelly MC, Sun D, et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999; 5: 1048-1051.
114. Wijnholds J, Mol CA, van Deemter L, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 2000; 97: 7476-7481.
115. Reid G, Wielinga P, Zelcer N, et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 2003; 63: 1094-1103.
116. Sampath J, Adachi M, Hatse S, et al. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS Pharm Sci 2002; 4: E14.
117. Adachi M, Sampath J, Lan LB, et al. Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J Biol Chem 2002; 277: 38998-39004.
118. Cooray HC, Blackmore CG, Maskell L, et al. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002; 13: 2059-2063.
119. Allen JD, Brinkhuis RF, Wijnholds J, et al. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999; 59: 4237-4241.
120. Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000; 92: 1651-1656.
121. Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002; 99: 15649-15654.
122. Wang X, Furakawa T, Nitanda T, et al. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol 2003; 63: 65-72.
123. Sugawara M, Huang W, Fei YJ, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci 2000; 89: 781-789.
124. Ganapathy ME, Huang W, Wang H, et al. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun 1998; 246: 470-475.
125. Guo A, Hu P, Balimane PV, et al. Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther 1999; 289: 448-454.
126. Cabrita MA, Baldwin SA, Young JD, et al. Molecular biology and regulation of nucleoside and nucleobase transporter proteins in eukaryotes and prokaryotes. Biochem Cell Biol 2002; 80: 623-638.
127. + nucleoside cotransporter CNT2. J Cereb Blood Flow Metab 2001; 21: 929-936.
128. Schaddelee MP, Voorwinden HL, van Tilburg EW, et al. Functional role of adenosine receptor subtypes in the regulation of blood-brain barrier permeability: possible implications for the design of synthetic adenosine derivatives. Eur J Pharm Sci 2003; 19: 13-22.
129. + nucleoside transporter CNT2 cloned from rat blood-brain barrier. J Pharmacol Exp Ther 2001; 299: 735-740.
130. Yao SY, Ng AM, Sundaram M, et al. Transport of antiviral 3′-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol 2001; 18: 161-167.
131. Wu X, Gutierrez MM, Giacomini KM. Further characterization of the sodium-dependent nucleoside transporter (N3) in choroid plexus from rabbit. Biochim Biophys Acta 1994; 1191: 190-196.
132. Hoesterey BL, Galinsky RE, Anderson BD. Dose dependence in the plasma pharmacokinetics and uptake kinetics of 2′,3′-dideoxyinosine into brain and cerebrospinal fluid of rats. Drug Metab Dispos 1991; 19: 907-912.
133. Thomas SA, Segal MB. The passage of azidodeoxythymidine into and within the central nervous system: does it follow the parent compound, thymidine? J Pharmacol Exp Ther 1997; 281: 1211-1218.
134. Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Arch 2004; 447: 666-676.
135. Sweet DH, Miller DS, Pritchard JB. Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus. J Biol Chem 2001; 276: 41611-41619.
136. Miller DS, Villalobos AR, Pritchard JB. Organic cation transport in rat choroid plexus cells studied by fluorescence microscopy. Am J Physiol 1999; 276: C955-C968.
137. Zhang L, Gorset W, Washington CB, et al. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos 2000; 28: 329-334.
138. Takeda M, Khamdang S, Narikawa S, et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther 2002; 300: 918-924.
139. Kikuchi R, Kusuhara H, Sugiyama D, et al. Contribution of organic anion transporter 3 (Slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-brain barrier. J Pharmacol Exp Ther 2003; 306: 51-58.
140. Nagata Y, Kusuhara H, Endou H, et al. Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol 2002; 61: 982-988.
141. Pritchard JB, Sweet DH, Miller DS, et al. Mechanism of organic anion transport across the apical membrane of choroid plexus. J Biol Chem 1999; 274: 33382-33387.
142. Alebouyeh M, Takeda M, Onozato ML, et al. Expression of human organic anion transporters in the choroid plexus and their interactions with neurotransmitter metabolites. J Pharmacol Sci 2003; 93: 430-436.
143. Wada S, Tsuda M, Sekine T, et al. Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J Pharmacol Exp Ther 2000; 294: 844-849.
144. Cihlar T, Lin DC, Pritchard JB, et al. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 1999; 56: 570-580.
145. Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001; 20: 641-648.
146. Wang Y, Sawchuk RJ. Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. J Pharm Sci 1995; 84: 871-876.
147. Takasawa K, Terasaki T, Suzuki H, et al. Distributed model analysis of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. J Pharmacol Exp Ther 1997; 282: 1509-1517.
148. Galinsky RE, Hoesterey BL, Anderson BD. Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. Life Sci 1990; 47: 781-788.
149. Fox E, Bungay PM, Bacher J, et al. Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. J Pharmacol Exp Ther 2002; 301: 1003-1011.
150. Wang Y, Wei Y, Sawchuk RJ. Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. J Pharm Sci 1997; 86: 1484-1490.
151. Hedaya MA, Sawchuk RJ. Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit. J Pharm Sci 1989; 78: 716-722.
152. Cretton EM, Schinazi RF, McClure HM, et al. Pharmacokinetics of 3′-azido-3′-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys. Antimicrob Agents Chemother 1991; 35: 801-807.
153. Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 2003; 1609: 1-18.
154. Yang Z, Brundage RC, Barbhaiya RH, et al. Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat. Pharm Res 1997; 14: 865-872.
155. Tuntland T, Ravasco RJ, al-Habet S, et al. Efflux of zidovudine and 2′,3′-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina. Pharm Res 1994; 11: 312-317.
156. Gibbs JE, Rashid T, Thomas SA. Effect of transport inhibitors and additional anti-HIV drugs on the movement of lamivudine (3TC) across the guinea pig brain barriers. J Pharmacol Exp Ther 2003; 306: 1035-1041.
157. de Miranda P, Good SS, Yarchoan R, et al. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin Pharmacol Ther 1989; 46: 494-500.
158. Hedaya MA, Elmquist WF, Sawchuk RJ. Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. Pharm Res 1990; 7: 411-417.
159. Kornhauser DM, Petty BG, Hendrix CW, et al. Probenecid and zidovudine metabolism. Lancet 1989; 2: 473-475.
160. Wong SL, Van Belle K, Sawchuk RJ. Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis. J Pharmacol Exp Ther 1993; 264: 899-909.
161. Pauli-Magnus C, Kroetz DL. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 2004; 21: 904-913.
162. Woodahl EL, Ho RJ. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 2004; 5: 11-19.
163. Gerloff T. Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 69-77.
164. Sparreboom A, Danesi R, Ando Y, et al. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Update 2003; 6: 71-84.
165. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
166. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30-36.
167. Nasi M, Borghi V, Pinti M, et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. Aids 2003; 17: 1696-1698.
168. Drozdzik M, Bialecka M, Mysliwiec K, et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003; 13: 259-263.
169. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348: 1442-1448.
170. Pauli-Magnus C, Feiner J, Brett C, et al. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther 2003; 74: 487-498.
171. Rosser LM, O'Donnell AM, Lee KM, et al. In vitro protein-binding characteristics of atevirdine and its N-dealkylated metabolite. Antiviral Res 1994; 25: 193-200.
172. Andersson LM, Hagberg L, Fuchs D, et al. Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals-correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels. J Neurovirol 2001; 7: 542-547.
173. Martin C, Albert J, Hansson P, et al. Cerebrospinal fluid mononuclear cell counts influence CSF HIV-1 RNA levels. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 214-219.
174. Marshall DW, Brey RL, Cahill WT, et al. Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. Arch Neurol 1988; 45: 954-958.
175. McRae MP, Brouwer KL, Kashuba AD. Cytokine regulation of P-glycoprotein. Drug Metab Rev 2003; 35: 19-33.
176. Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev 2002; 54: 1311-1331.
177. Jorajuria S, Dereuddre-Bosquet N, Naissant-Storck K, et al. Differential expression levels of MRP1, MRP4, and MRP5 in response to human immunodeficiency virus infection in human macrophages. Antimicrob Agents Chemother 2004; 48: 1889-1891.
178. Han H, Kim SG, Lee MG, et al. Mechanism of the reduced elimination clearance of benzylpenicillin from cerebrospinal fluid in rats with intracisternal administration of lipopolysaccharide. Drug Metab Dispos 2002; 30: 1214-1220.
179. Strazielle N, Khuth ST, Murat A, et al. Pro-inflammatory cytokines modulate matrix metalloproteinase secretion and organic anion transport at the blood-cerebrospinal fluid barrier. J Neuropathol Exp Neurol 2003; 62: 1254-1264.
180. Huang L, Wring SA, Woolley JL, et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001; 29: 754-760.
181. drugs.com. http://www.drugs.com
182. Gibbs JE, Jayabalan P, Thomas SA. Mechanisms by which 2′,3′-dideoxyinosine (ddI) crosses the guinea-pig CNS barriers; relevance to HIV therapy. J Neurochem 2003; 84: 725-734.
183. Thomas SA, Segal MB. The transport of the anti-HIV drug, 2′,3′-didehydro-3′-deoxythymidine (D4T), across the blood-brain and blood-cerebrospinal fluid barriers. Br J Pharmacol 1998; 125: 49-54.
184. Zimmerman TP, Mahony WB, Prus KL. 3′-azido-3′-deoxythymidine: an unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem 1987; 262: 5748-5754.
185. Stahle L, Oberg B. Pharmacokinetics and distribution over the blood brain barrier of two acyclic guanosine analogs in rats, studied by microdialysis. Antimicrob Agents Chemother 1992; 36: 339-342.
186. Daluge SM, Good SS, Faletto MB, et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 1997; 41: 1082-1093.